Position in FTRE
as of Jun 30, 2026
· filed Aug 7, 2026
Position Value
$687,282
+$306,526 QoQ
Shares Held
39,499
-2.3% QoQ
Ownership
0.042%
of shares outstanding
% of Portfolio
0.03%
of 13F equity value
Holder Rank
#115
of 331 holders
Holding Since
Jun 2025
5 quarters on record
Voting authority
Sole 1%
Shared 0%
None 99%
Common Shares in FTRE Over Time
Shares Held
Position Value (USD)
Position in Biotechnology
Healthcare · as of Jun 30, 2026Pallas Capital Advisors LLC holds $30,351,010 across 36 Biotechnology names. FTRE ranks #7 (2.3% of the industry book) .
| # | Ticker | Company | Shares | Value (USD) | Open |
|---|---|---|---|---|---|
| 1 | AXSM |
Axsome Therapeutics, Inc.
|
40,511 | $9,915,877 | |
| 2 | RPRX |
Royalty Pharma plc
|
108,585 | $6,088,360 | |
| 3 | INCY |
Incyte Corp
|
32,151 | $3,644,637 | |
| 4 | EXEL |
Exelixis, Inc.
|
30,721 | $1,671,529 | |
| 5 | REGN |
Regeneron Pharmaceuticals, Inc.
|
1,920 | $1,197,196 | |
| 6 | VRTX |
Vertex Pharmaceuticals Inc / Ma
|
2,200 | $1,092,806 | |
| 7 | FTRE |
Fortrea Holdings Inc.
This page
|
39,499 | $687,282 | |
| 8 | ALNY |
Alnylam Pharmaceuticals, Inc.
|
2,203 | $663,169 |
All Filings in FTRE
Export CSV
5 filing rows on record
| Report Date | Value (USD) | Shares | Type | Discretion | Filed | |
|---|---|---|---|---|---|---|
| 2026-06-30 | $687,282 | 39,499 | Shares | Sole | 2026-08-07 | |
| 2026-03-31 | $380,756 | 40,420 | Shares | Sole | 2026-04-21 | |
| 2025-12-31 | $683,531 | 39,625 | Shares | Sole | 2026-01-14 | |
| 2025-09-30 | $330,493 | 39,251 | Shares | Sole | 2025-11-07 | |
| 2025-06-30 | $231,893 | 46,942 | Shares | Sole | 2025-07-09 | |
| No filing history on record for this holder in this stock. | ||||||